| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 88 | 2022 | 11725 | 2.570 |
Why?
|
| Hypoglycemic Agents | 34 | 2021 | 2872 | 1.910 |
Why?
|
| Life Style | 36 | 2021 | 3835 | 1.520 |
Why?
|
| Metformin | 23 | 2020 | 835 | 1.270 |
Why?
|
| Weight Loss | 23 | 2020 | 2622 | 1.260 |
Why?
|
| Prediabetic State | 12 | 2021 | 499 | 1.120 |
Why?
|
| Fluorocarbons | 8 | 2021 | 452 | 0.980 |
Why?
|
| Blood Glucose | 28 | 2021 | 6256 | 0.890 |
Why?
|
| Cardiovascular Diseases | 23 | 2022 | 15165 | 0.760 |
Why?
|
| Alkanesulfonic Acids | 5 | 2021 | 180 | 0.760 |
Why?
|
| Environmental Pollutants | 8 | 2021 | 1179 | 0.750 |
Why?
|
| Exercise | 22 | 2022 | 5615 | 0.710 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2013 | 340 | 0.710 |
Why?
|
| Glucose Intolerance | 10 | 2020 | 577 | 0.670 |
Why?
|
| Cyclohexanes | 6 | 2013 | 152 | 0.650 |
Why?
|
| Insulin | 20 | 2014 | 6580 | 0.610 |
Why?
|
| Muscle Proteins | 7 | 1999 | 1159 | 0.600 |
Why?
|
| Diabetic Angiopathies | 12 | 2019 | 818 | 0.600 |
Why?
|
| Phenylalanine | 6 | 2013 | 365 | 0.590 |
Why?
|
| Monosaccharide Transport Proteins | 9 | 2001 | 440 | 0.580 |
Why?
|
| Overweight | 11 | 2021 | 2371 | 0.540 |
Why?
|
| Thiazolidinediones | 8 | 2013 | 476 | 0.510 |
Why?
|
| Diabetes Mellitus | 20 | 2017 | 5751 | 0.510 |
Why?
|
| Obesity | 27 | 2021 | 12745 | 0.500 |
Why?
|
| Endothelium, Vascular | 15 | 2013 | 4456 | 0.490 |
Why?
|
| Glucose | 8 | 2011 | 4397 | 0.440 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2015 | 3336 | 0.380 |
Why?
|
| Muscle, Skeletal | 12 | 2017 | 4931 | 0.370 |
Why?
|
| Risk Reduction Behavior | 6 | 2020 | 1125 | 0.370 |
Why?
|
| Insulin Resistance | 9 | 2021 | 3864 | 0.360 |
Why?
|
| Caprylates | 3 | 2019 | 111 | 0.350 |
Why?
|
| Hyperglycemia | 6 | 2010 | 1373 | 0.350 |
Why?
|
| Chromans | 4 | 2005 | 122 | 0.340 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 84 | 0.290 |
Why?
|
| Dietary Proteins | 1 | 2011 | 963 | 0.270 |
Why?
|
| Endocrine Disruptors | 2 | 2019 | 237 | 0.270 |
Why?
|
| Blood Pressure | 11 | 2020 | 8554 | 0.260 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2002 | 1116 | 0.250 |
Why?
|
| Vasodilation | 7 | 2014 | 944 | 0.240 |
Why?
|
| Brachial Artery | 6 | 2014 | 369 | 0.230 |
Why?
|
| Humans | 123 | 2022 | 744343 | 0.220 |
Why?
|
| Adipose Tissue | 4 | 2014 | 3279 | 0.220 |
Why?
|
| Middle Aged | 78 | 2021 | 213383 | 0.220 |
Why?
|
| Glucose Transporter Type 4 | 7 | 1999 | 250 | 0.210 |
Why?
|
| Comprehensive Health Care | 2 | 2015 | 127 | 0.210 |
Why?
|
| Male | 89 | 2021 | 350118 | 0.210 |
Why?
|
| Valine | 4 | 2013 | 413 | 0.200 |
Why?
|
| Caloric Restriction | 3 | 2018 | 302 | 0.200 |
Why?
|
| Adiponectin | 5 | 2015 | 1100 | 0.200 |
Why?
|
| Physical Fitness | 3 | 2016 | 733 | 0.200 |
Why?
|
| Cholesterol, HDL | 4 | 2016 | 1814 | 0.200 |
Why?
|
| Female | 83 | 2021 | 380194 | 0.190 |
Why?
|
| Microcirculation | 9 | 2004 | 1286 | 0.190 |
Why?
|
| Islets of Langerhans | 2 | 2004 | 1352 | 0.180 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2002 | 745 | 0.180 |
Why?
|
| Lipids | 4 | 2019 | 3305 | 0.180 |
Why?
|
| Body Weight | 7 | 2020 | 4669 | 0.180 |
Why?
|
| Behavior Therapy | 2 | 2017 | 865 | 0.180 |
Why?
|
| Body Mass Index | 15 | 2021 | 12720 | 0.170 |
Why?
|
| Triglycerides | 6 | 2016 | 2454 | 0.170 |
Why?
|
| Dyslipidemias | 3 | 2016 | 849 | 0.170 |
Why?
|
| Adiposity | 4 | 2020 | 1807 | 0.160 |
Why?
|
| Glucose Transporter Type 1 | 5 | 1996 | 192 | 0.160 |
Why?
|
| Thiazoles | 3 | 2003 | 1483 | 0.160 |
Why?
|
| Diet, Reducing | 4 | 2015 | 462 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2010 | 451 | 0.160 |
Why?
|
| Risk Factors | 32 | 2021 | 72290 | 0.160 |
Why?
|
| Drug Therapy, Combination | 9 | 2013 | 6489 | 0.160 |
Why?
|
| Diet | 6 | 2020 | 7939 | 0.160 |
Why?
|
| Tetrazoles | 4 | 2013 | 835 | 0.160 |
Why?
|
| Dioxoles | 1 | 1997 | 104 | 0.150 |
Why?
|
| Sulfonylurea Compounds | 1 | 1998 | 204 | 0.150 |
Why?
|
| Skin | 7 | 2004 | 4364 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2008 | 2531 | 0.140 |
Why?
|
| Aged | 43 | 2021 | 163280 | 0.140 |
Why?
|
| Aging | 2 | 2015 | 8664 | 0.140 |
Why?
|
| Fasting | 6 | 2012 | 1593 | 0.140 |
Why?
|
| Adult | 51 | 2022 | 214055 | 0.140 |
Why?
|
| Depression | 4 | 2019 | 7766 | 0.140 |
Why?
|
| Time | 1 | 2018 | 542 | 0.140 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2017 | 129 | 0.140 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 2838 | 0.140 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 54 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 550 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 1573 | 0.130 |
Why?
|
| Triazoles | 2 | 2013 | 911 | 0.130 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 346 | 0.130 |
Why?
|
| Pyrazines | 2 | 2013 | 1230 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2021 | 727 | 0.130 |
Why?
|
| Double-Blind Method | 12 | 2015 | 12026 | 0.130 |
Why?
|
| Glucose Tolerance Test | 5 | 2013 | 1150 | 0.120 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2015 | 434 | 0.120 |
Why?
|
| Placebos | 6 | 2013 | 1676 | 0.120 |
Why?
|
| Dietary Carbohydrates | 2 | 2017 | 906 | 0.120 |
Why?
|
| Growth Hormone | 1 | 1996 | 705 | 0.110 |
Why?
|
| Dietary Fiber | 1 | 2017 | 760 | 0.110 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 39050 | 0.110 |
Why?
|
| Energy Intake | 3 | 2017 | 2148 | 0.110 |
Why?
|
| Patient Education as Topic | 6 | 2017 | 2278 | 0.110 |
Why?
|
| Self Report | 2 | 2022 | 3558 | 0.110 |
Why?
|
| Vasculitis | 2 | 2007 | 519 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2017 | 604 | 0.110 |
Why?
|
| Receptors, Glucagon | 1 | 2013 | 92 | 0.110 |
Why?
|
| Calcinosis | 1 | 2021 | 1499 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2018 | 859 | 0.110 |
Why?
|
| Biological Transport | 5 | 1999 | 2118 | 0.110 |
Why?
|
| Heptanoic Acids | 2 | 2004 | 343 | 0.100 |
Why?
|
| Environmental Exposure | 3 | 2017 | 4234 | 0.100 |
Why?
|
| Speech Perception | 1 | 2017 | 489 | 0.100 |
Why?
|
| Incretins | 1 | 2012 | 88 | 0.100 |
Why?
|
| Oxidants, Photochemical | 1 | 2011 | 78 | 0.100 |
Why?
|
| Gastric Emptying | 1 | 2013 | 233 | 0.090 |
Why?
|
| Incidence | 11 | 2019 | 20947 | 0.090 |
Why?
|
| Diuretics | 1 | 2013 | 592 | 0.090 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 690 | 0.090 |
Why?
|
| Genetic Loci | 2 | 2017 | 2575 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2015 | 2373 | 0.090 |
Why?
|
| Venoms | 1 | 2010 | 91 | 0.090 |
Why?
|
| Cross-Sectional Studies | 11 | 2021 | 25043 | 0.090 |
Why?
|
| Disease Progression | 5 | 2017 | 13284 | 0.090 |
Why?
|
| Testosterone | 2 | 2016 | 2420 | 0.090 |
Why?
|
| Edema | 2 | 2004 | 789 | 0.090 |
Why?
|
| Iontophoresis | 4 | 2002 | 74 | 0.090 |
Why?
|
| Motor Cortex | 1 | 2017 | 986 | 0.080 |
Why?
|
| Health Services | 1 | 2014 | 758 | 0.080 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 1965 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 3255 | 0.080 |
Why?
|
| United States | 14 | 2021 | 69872 | 0.080 |
Why?
|
| Air Pollutants | 2 | 2014 | 2817 | 0.080 |
Why?
|
| Insulin Infusion Systems | 1 | 2010 | 212 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 15519 | 0.080 |
Why?
|
| Diabetes Complications | 3 | 2011 | 1359 | 0.080 |
Why?
|
| Ozone | 1 | 2011 | 469 | 0.080 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 1422 | 0.080 |
Why?
|
| Exercise Test | 3 | 2013 | 2074 | 0.080 |
Why?
|
| Diabetes, Gestational | 2 | 2014 | 1184 | 0.080 |
Why?
|
| Postprandial Period | 2 | 2007 | 292 | 0.080 |
Why?
|
| Internationality | 1 | 2013 | 1003 | 0.080 |
Why?
|
| Hormones, Ectopic | 2 | 2004 | 40 | 0.080 |
Why?
|
| Treatment Outcome | 12 | 2020 | 63114 | 0.080 |
Why?
|
| Cognition | 3 | 2020 | 6770 | 0.080 |
Why?
|
| Postpartum Period | 1 | 2014 | 1086 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 1240 | 0.080 |
Why?
|
| Particulate Matter | 2 | 2011 | 2530 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 2008 | 707 | 0.080 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2020 | 548 | 0.080 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 2007 | 9 | 0.080 |
Why?
|
| Pyrroles | 2 | 2004 | 1146 | 0.080 |
Why?
|
| Cell Membrane | 5 | 1999 | 3748 | 0.080 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 984 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 2731 | 0.070 |
Why?
|
| Drug Design | 1 | 2012 | 1076 | 0.070 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2007 | 59 | 0.070 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2007 | 91 | 0.070 |
Why?
|
| Hemoglobin A | 1 | 2007 | 87 | 0.070 |
Why?
|
| PPAR alpha | 1 | 2008 | 197 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2007 | 1155 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 281 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 1676 | 0.070 |
Why?
|
| Tyrosine | 2 | 2002 | 1461 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2021 | 5097 | 0.070 |
Why?
|
| Rats | 10 | 2002 | 24260 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2020 | 4043 | 0.070 |
Why?
|
| Polymorphism, Genetic | 3 | 2012 | 4328 | 0.070 |
Why?
|
| Cholesterol, LDL | 3 | 2016 | 2356 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 5 | 1998 | 8301 | 0.070 |
Why?
|
| Self Care | 2 | 2008 | 786 | 0.070 |
Why?
|
| Heart Rate | 2 | 2012 | 4091 | 0.070 |
Why?
|
| Diabetic Neuropathies | 2 | 2001 | 400 | 0.070 |
Why?
|
| Nitroglycerin | 2 | 2004 | 325 | 0.070 |
Why?
|
| Cohort Studies | 9 | 2019 | 40561 | 0.070 |
Why?
|
| Hypotension | 1 | 2011 | 884 | 0.070 |
Why?
|
| Disease Susceptibility | 3 | 2007 | 1782 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2017 | 1947 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2008 | 493 | 0.060 |
Why?
|
| Kidney | 4 | 2021 | 7186 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 214 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2012 | 3913 | 0.060 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 1210 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2018 | 6442 | 0.060 |
Why?
|
| Hormones | 2 | 2010 | 889 | 0.060 |
Why?
|
| Cholesterol | 2 | 2019 | 2917 | 0.060 |
Why?
|
| Body Composition | 1 | 2013 | 2401 | 0.060 |
Why?
|
| Heart Failure | 3 | 2021 | 10900 | 0.060 |
Why?
|
| Diuresis | 1 | 2004 | 116 | 0.060 |
Why?
|
| Blood Circulation | 1 | 2005 | 251 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 1889 | 0.060 |
Why?
|
| Ketosis | 1 | 2003 | 49 | 0.060 |
Why?
|
| Calcium | 1 | 2017 | 5756 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2007 | 1588 | 0.060 |
Why?
|
| Homocysteine | 1 | 2006 | 647 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 15076 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 2046 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 1790 | 0.060 |
Why?
|
| Creatinine | 1 | 2008 | 1919 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2007 | 293 | 0.050 |
Why?
|
| Microvessels | 2 | 2019 | 544 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 12354 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2010 | 832 | 0.050 |
Why?
|
| Acetylcholine | 5 | 2002 | 621 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 1343 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2020 | 53288 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 2849 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 658 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 1725 | 0.050 |
Why?
|
| Eating | 2 | 2000 | 1536 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 4420 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2003 | 526 | 0.050 |
Why?
|
| Glycogen | 1 | 2002 | 260 | 0.050 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 891 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 1261 | 0.050 |
Why?
|
| Risk | 2 | 2012 | 9687 | 0.050 |
Why?
|
| Hypoglycemia | 2 | 2009 | 861 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 57776 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2014 | 3209 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 440 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 3462 | 0.050 |
Why?
|
| Linear Models | 3 | 2019 | 5952 | 0.050 |
Why?
|
| C-Reactive Protein | 3 | 2007 | 3778 | 0.050 |
Why?
|
| Time Factors | 9 | 2020 | 40075 | 0.050 |
Why?
|
| Regression Analysis | 4 | 2014 | 6459 | 0.050 |
Why?
|
| Motor Activity | 2 | 2015 | 2714 | 0.050 |
Why?
|
| Nitroprusside | 4 | 2002 | 275 | 0.050 |
Why?
|
| Vitamin E | 1 | 2005 | 869 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 12245 | 0.050 |
Why?
|
| Water | 2 | 2004 | 1395 | 0.050 |
Why?
|
| Nervous System | 1 | 2003 | 554 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2013 | 5021 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2011 | 2149 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2003 | 2899 | 0.040 |
Why?
|
| Minority Groups | 1 | 2007 | 1223 | 0.040 |
Why?
|
| 5'-Nucleotidase | 2 | 1999 | 160 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2004 | 1869 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2003 | 1423 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2005 | 1125 | 0.040 |
Why?
|
| Prevalence | 4 | 2019 | 15226 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2005 | 1127 | 0.040 |
Why?
|
| Reflex | 1 | 2001 | 365 | 0.040 |
Why?
|
| Vasomotor System | 1 | 1999 | 209 | 0.040 |
Why?
|
| Animals | 13 | 2020 | 168757 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 1213 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2007 | 2263 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2011 | 3743 | 0.040 |
Why?
|
| Cell Fractionation | 1 | 1999 | 252 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 1660 | 0.040 |
Why?
|
| Risk Assessment | 8 | 2016 | 23338 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2011 | 3188 | 0.040 |
Why?
|
| Inflammation | 3 | 2008 | 10638 | 0.040 |
Why?
|
| Kinetics | 2 | 1996 | 6473 | 0.040 |
Why?
|
| Vitamin D | 1 | 2011 | 3223 | 0.040 |
Why?
|
| Peptides | 1 | 2010 | 4409 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2008 | 2684 | 0.040 |
Why?
|
| Particle Size | 2 | 2016 | 1642 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2008 | 2585 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6487 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 494 | 0.040 |
Why?
|
| Glucose Clamp Technique | 1 | 1997 | 266 | 0.040 |
Why?
|
| C-Peptide | 1 | 1998 | 419 | 0.040 |
Why?
|
| Seafood | 1 | 2020 | 384 | 0.040 |
Why?
|
| Seasons | 2 | 2014 | 1493 | 0.040 |
Why?
|
| Proteins | 2 | 2010 | 6103 | 0.040 |
Why?
|
| Boston | 4 | 2014 | 9313 | 0.040 |
Why?
|
| Hypertension | 3 | 2011 | 8480 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 452 | 0.040 |
Why?
|
| Regional Blood Flow | 3 | 2005 | 1525 | 0.040 |
Why?
|
| Mental Status Schedule | 1 | 2017 | 321 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 2 | 1999 | 1602 | 0.040 |
Why?
|
| Temperature | 2 | 2014 | 2206 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 9959 | 0.030 |
Why?
|
| Heredity | 1 | 2016 | 154 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2007 | 7913 | 0.030 |
Why?
|
| Forearm | 3 | 2004 | 409 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1996 | 349 | 0.030 |
Why?
|
| Phlorhizin | 1 | 1995 | 37 | 0.030 |
Why?
|
| Arteries | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2013 | 2618 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1998 | 648 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1996 | 402 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1997 | 402 | 0.030 |
Why?
|
| Epididymis | 1 | 1997 | 227 | 0.030 |
Why?
|
| Hand Strength | 1 | 2018 | 448 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 1889 | 0.030 |
Why?
|
| Body Size | 1 | 2018 | 461 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2013 | 12208 | 0.030 |
Why?
|
| Leisure Activities | 2 | 2008 | 311 | 0.030 |
Why?
|
| Leptin | 1 | 2003 | 1599 | 0.030 |
Why?
|
| Streptozocin | 1 | 1995 | 196 | 0.030 |
Why?
|
| Epinephrine | 1 | 1998 | 792 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 1999 | 846 | 0.030 |
Why?
|
| Solubility | 3 | 2003 | 1085 | 0.030 |
Why?
|
| Reference Values | 4 | 2004 | 4982 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 9648 | 0.030 |
Why?
|
| von Willebrand Factor | 3 | 2006 | 669 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 723 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Genotype | 3 | 2013 | 12951 | 0.030 |
Why?
|
| Weight Gain | 3 | 2014 | 2292 | 0.030 |
Why?
|
| Evoked Potentials, Motor | 1 | 2017 | 454 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 17446 | 0.030 |
Why?
|
| Research Design | 3 | 2019 | 5987 | 0.030 |
Why?
|
| Resistin | 2 | 2004 | 170 | 0.030 |
Why?
|
| Rats, Inbred Lew | 3 | 2002 | 1162 | 0.030 |
Why?
|
| Vasodilator Agents | 3 | 2004 | 977 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2015 | 320 | 0.030 |
Why?
|
| Humidity | 1 | 2014 | 197 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1999 | 1203 | 0.030 |
Why?
|
| Prognosis | 3 | 2021 | 29063 | 0.030 |
Why?
|
| Quality of Life | 1 | 2014 | 12804 | 0.030 |
Why?
|
| Axons | 1 | 2001 | 1684 | 0.030 |
Why?
|
| Indian Ocean | 1 | 2011 | 12 | 0.030 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1994 | 370 | 0.030 |
Why?
|
| Indians, North American | 2 | 2007 | 355 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 1995 | 293 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 1995 | 415 | 0.030 |
Why?
|
| Liposomes | 1 | 1995 | 759 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2005 | 3670 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 2327 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2282 | 0.030 |
Why?
|
| Electromyography | 1 | 2017 | 1379 | 0.030 |
Why?
|
| Air Pollution | 1 | 2005 | 2286 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 21683 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1999 | 5179 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6538 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2014 | 1590 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 9583 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1995 | 789 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2016 | 2634 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2017 | 2539 | 0.020 |
Why?
|
| Morbidity | 1 | 1995 | 1769 | 0.020 |
Why?
|
| Aspirin | 1 | 2002 | 3282 | 0.020 |
Why?
|
| Health Education | 1 | 2016 | 1056 | 0.020 |
Why?
|
| Smoking | 1 | 2006 | 8987 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2017 | 2017 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2014 | 575 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1999 | 2938 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2013 | 604 | 0.020 |
Why?
|
| Biopsy | 2 | 2002 | 6756 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4933 | 0.020 |
Why?
|
| Safety | 2 | 2004 | 1186 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2010 | 168 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2003 | 13989 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 6038 | 0.020 |
Why?
|
| Cytokines | 1 | 2003 | 7322 | 0.020 |
Why?
|
| Albuminuria | 2 | 2005 | 682 | 0.020 |
Why?
|
| Endothelins | 1 | 2008 | 138 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 5391 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2013 | 5102 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 163 | 0.020 |
Why?
|
| Methylglycosides | 1 | 1987 | 10 | 0.020 |
Why?
|
| Methylglucosides | 1 | 1987 | 36 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 878 | 0.020 |
Why?
|
| Social Support | 1 | 2017 | 2118 | 0.020 |
Why?
|
| Swine | 1 | 1997 | 5917 | 0.020 |
Why?
|
| Health Status | 2 | 2013 | 4034 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2017 | 1432 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 840 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 77449 | 0.020 |
Why?
|
| Liver | 1 | 2002 | 7474 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2019 | 3748 | 0.020 |
Why?
|
| Myocardium | 1 | 1999 | 4776 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2014 | 2488 | 0.020 |
Why?
|
| Albumins | 1 | 2008 | 569 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2013 | 2019 | 0.020 |
Why?
|
| Foot | 2 | 2001 | 527 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2011 | 1354 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 2459 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2017 | 3107 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 10943 | 0.020 |
Why?
|
| Pregnancy | 3 | 2014 | 29144 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 1903 | 0.020 |
Why?
|
| Child | 3 | 2010 | 77709 | 0.020 |
Why?
|
| Adolescent | 3 | 2010 | 85781 | 0.020 |
Why?
|
| Sulfates | 1 | 2005 | 390 | 0.010 |
Why?
|
| Case-Control Studies | 3 | 2013 | 21746 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 2004 | 186 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 6993 | 0.010 |
Why?
|
| Amino Acids | 1 | 2010 | 1736 | 0.010 |
Why?
|
| Kidney Medulla | 1 | 2004 | 182 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8642 | 0.010 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1983 | 25 | 0.010 |
Why?
|
| Glyburide | 1 | 2003 | 113 | 0.010 |
Why?
|
| Retinol-Binding Proteins | 1 | 1983 | 65 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13408 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 7799 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2703 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2010 | 2126 | 0.010 |
Why?
|
| Glucose-6-Phosphate | 1 | 2002 | 30 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2005 | 597 | 0.010 |
Why?
|
| Blood Volume | 1 | 2003 | 565 | 0.010 |
Why?
|
| Glycogen Synthase | 1 | 2002 | 62 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3760 | 0.010 |
Why?
|
| Spain | 1 | 2003 | 465 | 0.010 |
Why?
|
| Transferrin | 1 | 1983 | 295 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2004 | 936 | 0.010 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2002 | 242 | 0.010 |
Why?
|
| Carbon | 1 | 2005 | 687 | 0.010 |
Why?
|
| Alleles | 1 | 2012 | 6933 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1996 | 13033 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6544 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2002 | 689 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 916 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 625 | 0.010 |
Why?
|
| Receptor, EphA8 | 1 | 1998 | 4 | 0.010 |
Why?
|
| Young Adult | 3 | 2010 | 56430 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 2297 | 0.010 |
Why?
|
| Educational Status | 1 | 2007 | 2540 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16365 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2505 | 0.010 |
Why?
|
| Signal Transduction | 2 | 1999 | 23403 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1092 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 2902 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 1998 | 148 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 871 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 1998 | 205 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 1999 | 314 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 12261 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7785 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 4215 | 0.010 |
Why?
|
| Phosphorylation | 2 | 1999 | 8436 | 0.010 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 1999 | 563 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3701 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 1423 | 0.010 |
Why?
|
| Stroke | 1 | 2019 | 9981 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 6365 | 0.010 |
Why?
|
| Premenopause | 1 | 1999 | 1033 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 35421 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 10397 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1997 | 930 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 2969 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 3200 | 0.010 |
Why?
|
| Pregnancy in Diabetics | 1 | 1994 | 179 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1994 | 286 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 7149 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 4189 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 5985 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15540 | 0.010 |
Why?
|
| Physical Examination | 1 | 1997 | 1237 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18370 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1998 | 1640 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1998 | 1660 | 0.010 |
Why?
|
| Postmenopause | 1 | 1999 | 2461 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1999 | 2440 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 8324 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 10388 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 11366 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 13881 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1999 | 2915 | 0.010 |
Why?
|
| Health Behavior | 1 | 2000 | 2636 | 0.000 |
Why?
|
| Chronic Disease | 1 | 2003 | 9146 | 0.000 |
Why?
|
| 3-O-Methylglucose | 1 | 1987 | 37 | 0.000 |
Why?
|
| Cytochalasin B | 1 | 1987 | 74 | 0.000 |
Why?
|
| Nucleotidases | 1 | 1987 | 31 | 0.000 |
Why?
|
| NADH Dehydrogenase | 1 | 1987 | 41 | 0.000 |
Why?
|
| Massachusetts | 1 | 2000 | 8663 | 0.000 |
Why?
|
| Microsomes | 1 | 1987 | 257 | 0.000 |
Why?
|
| Heart Diseases | 1 | 2000 | 2788 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2186 | 0.000 |
Why?
|
| Galactosyltransferases | 1 | 1987 | 263 | 0.000 |
Why?
|
| Prealbumin | 1 | 1983 | 210 | 0.000 |
Why?
|
| Mice | 1 | 2008 | 81183 | 0.000 |
Why?
|
| Protein Binding | 1 | 1983 | 9386 | 0.000 |
Why?
|